Treats myasthenia gravis. ANDA 40512, held by Ani Pharms. Pyridostigmine Bromide.
As of Nov 16, 2026, ANDA 40512 (Pyridostigmine Bromide), held by Ani Pharms, was first approved by FDA on Oct 8, 2003, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Pyridostigmine Bromide Tablets USP are useful in the treatment of myasthenia gravis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 8, 2003 | Original application | Approved |
| Pyridostigmine Bromide60MG · tablet;oral | Pyridostigmine Bromide | Rx |
| Pyridostigmine Bromide30MG · tablet;oral | Pyridostigmine Bromide | Discontinued |
| Jul 20, 2005 | Supplement 3Labeling | Approved | None posted |
| Oct 8, 2003 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters